包装
胶囊
250毫克:
28粒(瓶装)
100粒(瓶装)
贮法
使用期限等
贮法
気密容器、室温保存
使用期限
外箱に表示(5年)
製造和銷售
小野薬品工業株式会社 注:以上中文不够完整,使用者以原处方资料为准。
完整说明附件: https://www.info.pmda.go.jp/go/pack/2190038M1024_1_02/
--------------------------------------------------------
On the January 18, 2019, Ono Pharmaceutical, a Japanese pharmaceutical company, announced that Demser (Metyrosine, methyl tyrosine, デムサーカプセル) 250mg capsule had been approved by the Japanese regulatory agency, a tyrosine hydroxylase inhibitor,Used in patients with pheochromocytoma (PC) to improve the excessive secretion of catecholamines.
Pheochromocytoma (PC) is a neuroendocrine tumor that originates from the adrenal medulla or the outer adrenal ganglion, and there are an estimated 2920 patients in Japan.
Excessive secretion of catecholamines can cause a variety of symptoms, such as tachycardia, headache, panic, sweating, constipation, and high blood pressure. Sympathetic drugs, alpha blockers and beta-blockers, are used to control blood pressure and heart rate and are often used to improve these symptoms.
In many patients with local invasive or metastatic malignant PCs, long-acting therapies, such as radiotherapy and chemotherapy, are required because surgical resection of the tumour is not applicable.
Chronic persistent excessive secretion of catecholamines may increase the risk ofcardiovascular related adverse events, such as heart failure or fatal arrhythmia.
Demser inhibits tyrosine hydroxylase associated with catecholamines, greatly reduces catecholamines secreted by PCs, and reduces symptoms caused by excessive catecholamine secretion demser is a promising drug that has been shown to improve disease symptoms in patients receiving sympathetic drugs that do not adequately control symptoms.
In Japan, Demser was awarded orphan medicine by the Japanese Ministry of Health, Labour and Welfare (MHLW) in May 2015.